Loading stock data…
NRXS
$8.08+0.63 (+8.46%)
Market ClosedLast close May 1
NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
NeurAxis, Inc. in the Healthcare sector is trading at $8.08. The stock is currently near its 52-week high of $8.40, remaining 96.6% above its 200-day moving average. Technical signals show neutral RSI of 65 and bullish MACD crossover, explaining why NRXS maintains its current momentum and trend strength. The Whystock Score of 75/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Neutral momentum (RSI 65) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$8.08
Potential Upside
5%
Whystock Fair Value$8.48
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimula...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$84.02M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.89
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-229.47%
Volume
Today's trading volume
293,069
Recent News
NeurAxis Stock Gains Post Q4 Earnings on Strong Revenue Growth
NRXS witnesses strong revenue growth and expanding coverage in fourth-quarter 2025, but rising costs and commercialization investments weigh on profitability.
Neuraxis Inc (NRXS) Q4 2025 Earnings Call Highlights: Revenue Growth Amidst Operational Challenges
Neuraxis Inc (NRXS) reports a 27% revenue increase in Q4 2025, while navigating higher operating expenses and strategic expansions.
NeurAxis, Inc. Q4 2025 Earnings Call Summary
Moby summary of NeurAxis, Inc.'s Q4 2025 earnings call
Top Stock Reports for Meta, Bank of America & Procter & Gamble
Meta Platforms leads today's Zacks Research Daily as analysts highlight strong user growth, heavier AI investment and lingering concerns around monetization.
NRXS Stock Declines Post Q3 Earnings Despite Continued Revenue Growth
NeurAxis posts its fifth straight quarter of double-digit expansion, but rising costs and margin pressure weigh on third-quarter 2025 results.